In this work, we summarize a comprehensive spectrum of SEC23B variants, describe nine new CDA II cases accounting for six previously unreported variants, and discuss innovative therapeutic approaches for CDA II. The gene discussed is SEC23B; the disease is congenital dyserythropoietic anemia type 2.